Source comparison
CJC-1295 vs GHRP-2 Acetate: Research Application Comparison
Mechanism of Action GHRH analogue; binds albumin to extend half-life and amplify GH pulse amplitude Ghrelin mimetic; activates GHS-R1a to trigger rapid, high-frequency GH pulses Different receptor pathways. CJC-1295 sustains baseline elevation; GHRP-2 replicat
This comparison does not assign a generated winner or score.
- Mechanism of Action
- GHRH analogue; binds albumin to extend half-life and amplify GH pulse amplitude
- Ghrelin mimetic; activates GHS-R1a to trigger rapid, high-frequency GH pulses
- Different receptor pathways. CJC-1295 sustains baseline elevation; GHRP-2 replicates natural pulsatility
- Half-Life
- 6–8 days (albumin-bound)
- 30–60 minutes (free peptide)
- CJC-1295 allows weekly dosing; GHRP-2 requires 2–3 daily administrations
- IGF-1 Elevation
- 60–90% above baseline, sustained 10–14 days
- 50–110% above baseline, returns to baseline within 7 days of discontinuation
- CJC-1295 for sustained anabolic signalling; GHRP-2 for pulse-frequency research
- Typical Dose
- 1–2 mg weekly or bi-weekly
- 100–300 mcg 2–3× daily
- Dose frequency determines protocol complexity and temporal control
- Reconstitution Stability
- 28 days at 2–8°C
- 14 days at 2–8°C
- CJC-1295 tolerates longer storage; GHRP-2 requires faster utilisation
- Synergy Potential
- Amplifies baseline GH; works synergistically with GHS compounds
- Increases pulse frequency; complements GHRH analogues
- Co-administration produces 3.5× greater IGF-1 increase vs monotherapy